Abstract
Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.
Original language | English (US) |
---|---|
Pages (from-to) | 135-152 |
Number of pages | 18 |
Journal | Advances in Therapy |
Volume | 35 |
Issue number | 2 |
DOIs | |
State | Published - Feb 1 2018 |
Keywords
- Adult T-cell leukemia–lymphoma
- Chemotherapy
- Human T-cell lymphotropic virus type 1
- Oncology
- Relapsed/refractory disease
- Targeted agents
ASJC Scopus subject areas
- Pharmacology (medical)